3. Liu K, Ding H, Xu B, et al. Clinical analysis of non-AIDS patients pathologically diagnosed with pulmonary cryptococcosis. J Thorac Dis, 2016, 8(10): 2813-2821.
[4]
4. Brizendine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS One, 2013, 8(3): e60431.
[5]
5. Hsu LY, Ng ES, Koh LP. Common and emerging fungal pulmonary infections. Infect Dis Clin North Am, 2010, 24(3): 557-577.
9. Kim DY, Kim Y, Baek SY, et al. Simultaneous thoracic and abdominal presentation of disseminated cryptococcosis in two patients without HIV infection. Am J Roentgenol, 2003, 181(4): 1055-1057.
12. Chang WC, Tzao C, Hsu HH, et al. Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest, 2006, 129(2): 333-340.
[13]
13. Zhang Y, Li N, Zhang Y, et al. Clinical analysis of 76 patients pathologically diagnosed with pulmonary cryptococcosis. Eur Respir J, 2012, 40(5): 1191-1200.
[14]
14. Xie LX, Chen YS, Liu SY, et al. Pulmonary cryptococcosis: comparison of CT findings in immunocompetent and immunocompromised patients. Acta Radiol, 2015, 56(4): 447-453.
[15]
15. Yamakawa H, Yoshida M, Yabe M, et al. Correlation between clinical characteristics and chest computed tomography findings of pulmonary cryptococcosis. Pulm Med, 2015, 2015: 703407.
[16]
16. Kerkering TM, Duma RJ, Shadomy S. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med, 1981, 94(5): 611-616.
[17]
17. Slade E, Tamber PS, Vincent JL. The Surviving Sepsis Campaign: raising awareness to reduce mortality. Crit Care, 2003, 7(1): 1-2.
[18]
18. Pongmekin P, Chongtrakool P, Santanirand P, et al. Clinical characteristics and mortality risk factors of cryptococcal infection among HIV-negative patients. J Med Assoc Thai, 2014, 97(1): 36-43.
[19]
19. Mahabeer Y, Chang CC, Naidu D, et al. Comparison of Etests and Vitek 2? to broth microdilution for the susceptibility testing of Cryptococcus neoformans. Diagn Microbiol Infect Dis, 2014, 80(4): 294-298.
[20]
20. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis, 2010, 50(3): 291-322.